MTVA

SEC filing MTVA Presents DA-1726 Phase 1 Results, 9.1% Mean Body Weight Reduction at Day 54, Favorable Tolerability and Exploratory Liver Improvements

6d ago

Scanner Large up move: 53.7% (3.4x normal daily movement)

11d ago

Scanner Large up move: 69.4% (3.4x normal daily movement)

13d ago

SEC filing MTVA to Present 3 Late-Breaking Obesity & MASH Data at ADA 2026 Sessions

15d ago

SEC filing MTVA to Present DA-1726 GLP-1/Glucagon Dual Agonist Data at EASL Congress 2026

22d ago

SEC filing MTVA Doses First Patient in 48‑64 mg DA‑1726 Phase 1 Obesity Study, 40‑Subject Trial, Dual GLP‑1/GCGR Agonist

53d ago

News Billionaire Johnson’s VC Fund Is Said to Shelve Sale of 40 China Tech Firms

112d ago

News Meta Stock Carries Slump In 2026. Here's What Wall Street Is Saying Ahead Of Q4 Results.

132d ago

News MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

136d ago

News MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

138d ago

News MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

148d ago